Diagnosing transthyretin amyloid cardiomyopathy (ATTR-CM) is challenging because its symptoms are vague and overlap with many conditions. Providers typically follow a stepwise approach that combines history-taking, targeted testing, and imaging to confirm the diagnosis and identify its type.
According to VeryWell Health, getting to suspicion starts with a medical history and physical exam. Clinicians ask about family history of heart disease, heart failure, or cardiomyopathy and look for red flags that justify further workup. Genetic testing then helps distinguish wild-type from hereditary ATTR-CM. When hereditary disease is found, first-degree relatives should be offered testing.
No single cardiac test clinches ATTR-CM early on, but several provide critical clues:
- Echocardiogram: Cannot diagnose ATTR-CM by itself, but may raise suspicion based on structural and functional patterns.
- EKG: A noninvasive look at cardiac electrical activity; about 40% of people with ATTR-CM show low-voltage patterns. While not diagnostic, this can aid screening and context.
- Cardiac MRI (CMR): Offers detailed structural imaging and can exclude other causes of heart changes. Findings may be suggestive of amyloidosis, but CMR alone does not diagnose ATTR-CM.
- Nuclear scintigraphy: The mainstay diagnostic tool. A tiny amount of tracer binds to amyloid deposits, allowing visualization and semi-quantification of cardiac amyloid burden on scanning.
Laboratory evaluation is essential to rule out other amyloid types, particularly light-chain (AL) amyloidosis, which demands different treatment. Serum and urine tests assess abnormal free light chains and monoclonal proteins—markers usually absent in ATTR-CM. While blood tests cannot confirm ATTR-CM, they narrow the differential and guide imaging and genetics.
Biopsy can support diagnosis, often starting with a fat pad biopsy. This minimally invasive sample can confirm the presence of amyloid using special stains, though it cannot determine type, necessitating further testing to differentiate ATTR from AL. It’s a useful first step when a cardiac biopsy isn’t needed or feasible.
Who gets ATTR-CM? There are two forms:
- Hereditary ATTR-CM results from an inherited mutation that misshapes transthyretin. It is more common in people from Portugal, Brazil, Japan, and Sweden, and a U.S. variant affects 3% to 4% of African Americans.
- Wild-type ATTR-CM is an age-related change, typically occurring in men over 60.
Symptoms often include shortness of breath, lower-limb swelling, chest congestion, coughing, wheezing, increased heart rate, confusion, and palpitations. Wild-type disease may also present with carpal tunnel syndrome and spinal stenosis.
Treatment has advanced from symptom control to disease modification. While current medicines do not reverse established heart damage, they can slow progression: Amvuttra (vutrisiran) reduces transthyretin production, and Attruby (acoramidis) plus Vyndamax/Vyndaqel (tafamidis) stabilize the liver-produced protein.
Bottom line: ATTR-CM stiffens the heart and impairs pumping. Diagnosis relies on a combination of EKG, echocardiogram, nuclear imaging, labs, and genetics. If you have suggestive symptoms or a family history, seek medical evaluation.
